Effect of Strontium Ranelate on the Muscle and Vertebrae of Ovariectomized Rats
- 188 Downloads
Osteoporosis is often accompanied by sarcopenia. The effect of strontium ranelate (SR) on muscle tissue has not been investigated sufficiently. In this study, the effect of different SR treatments on muscle was studied. Additionally, the lumbar vertebrae were analyzed. Three-month-old female rats were divided into five groups (n = 12): Group 1: untreated (NON-OVX); Group 2: ovariectomized and left untreated (OVX); Group 3: SR after OVX until the study ended (13 weeks, SR prophylaxis and therapy = pr+th); Group 4: OVX and SR for 8 weeks (SR prophylaxis = pr); Group 5: SR for 5 weeks from the 8 week after OVX (SR therapy = SR th). SR was applied in food (630 mg/kg body weight). The size of muscle fibers, capillary density, metabolic enzymes, and mRNA expression were assessed in soleus, gastrocnemius, and longissimus muscles. The vertebral bodies underwent micro-CT, biomechanical, and ashing analyses. In general, SR did not alter the muscle histological parameters. The changes in fiber size and capillary ratio were related to the body weight. Myostatin mRNA was decreased in Sr pr+th; protein expression was not changed. SR th led to increase in mRNA expression of vascular endothelial growth factor (Vegf-B). In lumbar spine, SR pr+th enhanced biomechanical properties, bone mineral density, trabecular area, density, and thickness and cortical density. The reduced calcium/phosphate ratio in the SR pr+th group indicates the replacement of calcium by strontium ions. SR has no adverse effects on muscle tissue and it shows a favorable time-dependent effect on vertebrae. A functional analysis of muscles could verify these findings.
KeywordsStrontium ranelate Osteoporosis Muscle Ovariectomized rat
We wish to express our gratitude to Elsbeth Bonhoff Stiftung for providing the financial support for the present study (Grant N70). Moreover, we are grateful to R. Wigger, R. Castro-Machguth, and A. Witt for the technical support they provided.
Compliance with Ethical Standards
Conflict of interest
Authors D. Saul, B. Harlas, A. Ahrabi, R. L. Kosinsky, D. B. Hoffmann, M. Wassmann, R. Wigger, K. O. Böker, S. Sehmisch, and M. Komrakova declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
- 6.DVO (2014) OSTEOPOROSE bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen: Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.VGoogle Scholar
- 7.Reginster JY, Seeman E, Vernejoul MC de et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90(5):2816–2822. https://doi.org/10.1210/jc.2004-1774 CrossRefPubMedGoogle Scholar
- 8.Kanis JA, Johansson H, Oden A et al (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 22(8):2347–2355. https://doi.org/10.1007/s00198-010-1474-0 CrossRefPubMedGoogle Scholar
- 20.Molinuevo MS, Fernandez JM, Cortizo AM et al (2017) Advanced glycation end products and strontium ranelate promote osteogenic differentiation of vascular smooth muscle cells in vitro: preventive role of vitamin D. Mol Cell Endocrinol 450:94–104. https://doi.org/10.1016/j.mce.2017.04.022 CrossRefPubMedGoogle Scholar
- 21.Servier Laboratories Limited (2016) Protelos: summary of product characteristics (SPC)–(eMC). https://www.medicines.org.uk/emc/medicine/15410. Accessed 24 Nov 2016
- 30.Andersen P (1975) Capillary density in skeletal muscle of man. Acta Physiol Scand 95(2):203–205. https://doi.org/10.1111/j.1748-1716.1975.tb10043.x CrossRefPubMedGoogle Scholar
- 34.Hatefi Y, Stiggall DL (1978)  Preparation and properties of NADH: Cytochrome c oxidoreductase (complex I–III). In: Fleischer S (ed) Biological oxidations: mitochondrial and microbial systems, vol 53. Academy Press, New York, pp 5–10Google Scholar
- 46.Dachverband OeV (2014) Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V.: Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen. http://www.dv-osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20Kurzfassung%20und%20Langfassung%20Version%201a%2012%2001%202016.pdf. Accessed 10 Dec 2017
- 58.Body JJ, Bergmann P, Boonen S et al. (2012) Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (23 Suppl 1): S1–S23. https://doi.org/10.1007/s00198-011-1891-8
- 59.EMEA (2005) EPAR: scientific discussion: european medicines agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000560/WC500045522.pdf. Accessed 10 Dec 2017